Leukemic arthritis and severe hypercalcemia in a man with chronic myeloid leukemia: A case report and review of the literature

被引：4
作者：
Rujirachun P. [1 ]
Junyavoraluk A. [1 ]
Owattanapanich W. [2 ]
Suvannarerg V. [1 ,3 ]
Sirinvaravong S. [1 ,4 ]
机构：
[1] Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
[2] Division of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok
[3] Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok
[4] Division of Endocrine and Metabolism, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok
来源：
Journal of Medical Case Reports | / 12卷 / 1期
关键词：
Chronic myeloid leukemia; Hypercalcemia; Leukemic arthritis; Osteolytic bone;
D O I：
10.1186/s13256-018-1798-5
中图分类号：
学科分类号：
摘要：
Background: Patients with chronic myeloid leukemia typically present with high white blood cell counts revealed during annual checkups. Leukemic arthritis and hypercalcemia are rare manifestations in patients with chronic myeloid leukemia. Case presentation: A 35-year-old Thai man who had been diagnosed with chronic myeloid leukemia in the chronic phase developed blast crisis while he was receiving ongoing treatment with imatinib at 400 mg/day. Initially, he presented with oligoarthritis in both knees and ankles. A bone scintigraphy showed a prominent bony uptake, with a symmetrical, increased uptake in many bone areas. Induction therapy with a 7 + 3 induction regimen was prescribed in conjunction with 600 mg of imatinib once daily before switching to 140 mg of dasatinib. He subsequently developed severe hypercalcemia (total serum calcium of 17.8 mg/dL), with generalized osteolytic lesions detected on a bone survey. His serum vitamin D level was 50.64 ng/mL, while the serum parathyroid hormone level was 9.82 pg/mL. Despite the administration of an aggressive intravenously administered hydration, intravenously administered calcitonin, and 600 mg/day of imatinib, the severe hypercalcemia was refractory. We therefore decided to prescribe 20 mg/day of intravenously administered dexamethasone; fortunately, his serum calcium level decreased dramatically to normal range within a few days. Conclusions: Although leukemic arthritis and severe hypercalcemia are extraordinary presentations in patients with chronic myeloid leukemia, the advanced phase of the disease might bring on these symptoms. Apart from parathyroid hormone-related protein-related hypercalcemia, vitamin D is a mechanism of humoral-mediated hypercalcemia. © 2018 The Author(s).
引用
收藏
相关论文
共 26 条
  • [1] Hochhaus A., Saussele S., Rosti G., Mahon F.X., Janssen J., Hjorth-Hansen H., Et al., Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 28, pp. iv41-iv51, (2017)
  • [2] Acree S.C., Pullarkat S.T., Quismorio F.P., Mian S.R., Brynes R.K., Adult leukemic synovitis is associated with leukemia of monocytic differentiation, J Clin Rheumatol, 17, 3, pp. 130-134, (2011)
  • [3] Tebben P.J., Singh R.J., Kumar R., Vitamin D-mediated hypercalcemia: Mechanisms, diagnosis, and treatment, Endocr Rev, 37, 5, pp. 521-547, (2016)
  • [4] Toro-Tobon D., Agosto S., Ahmadi S., Koops M., Bruder J.M., Chronic myeloid leukemia associated hypercalcemia: A case report and literature review, Am J Case Rep, 18, pp. 203-207, (2017)
  • [5] Joyner M.V., Dujardin P., Cassuto J.P., Audoly P., Hypercalcaemia as complication of accelerated chronic granulocytic leukaemia, Br Med J, 2, 6094, (1977)
  • [6] Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J.F., Et al., European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013, Blood, 122, 6, pp. 872-884, (2013)
  • [7] Sahu K.K., Malhotra P., Uthamalingam P., Prakash G., Bal A., Varma N., Et al., Chronic myeloid leukemia with extramedullary blast crisis: Two unusual sites with review of literature, Indian J Hematol Blood Transfus, 32, pp. 89-95, (2016)
  • [8] Louthrenoo W., Kasitanon N., Sukitawut W., Arthritis in leukemia, J Clin Rheumatol, 6, 6, pp. 313-317, (2000)
  • [9] Ballard H.S., Marcus A.J., Hypercalcemia in chronic myelogenous leukemia, N Engl J Med, 282, 12, pp. 663-665, (1970)
  • [10] Kubonishi I., Asahi Y., Machida H., Uemura Y., Hatakeyama N., Kubota T., Et al., PTHrP-mediated hypercalcaemia in a case of CML blast crisis, Br J Haematol, 96, 1, pp. 165-167, (1997)
123